NOVEL LINEAR PEPTIDE UNIVERSAL MALARIA VACCINES

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 这项研究建议的总体目标是优化疟疾模块嵌合疫苗(MCV)的设计、组成和配方，作为在流行地区控制疾病的有效干预措施。第一个具体目标将集中在开发战略，以构建和提供稳定和有效的MCV，以保护恒河猴免受猴疟疾寄生虫食蟹猴的实验挑战。该项目的第二个目标将建立在设计具有潜在保护人类免受间日疟原虫感染的MCV所获得的经验的基础上。由间日疟原虫引起的疟疾是一个主要的世界性健康问题，估计每年有8000万病例。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The overall goal of this research proposal is to optimize the design, composition and formulation of malaria Modular Chimeric Vaccines (MCVs) as effective intervention measures to control the disease in endemic areas. The first specific aim will focus on developing strategies to construct and deliver stable and efficacious MCVs that can protect rhesus macaques against the experimental challenge with a simian malaria parasite Plasmodium cynomolgi. The second aim of the project will build on the experience gained to design MCVs with the potential to protect humans against P. vivax. Malaria caused by P. vivax is a major worldwide health problem with an estimated 80 million cases annually.